

# DURAFIBER\* Ag Strength in performance and design





### **Indications**

DURAFIBER° Ag is designed to be left in place for up to 7 days<sup>2-4</sup> It can be applied to chronic and acute wounds including:

- Leg ulcers
- Pressure injuries
- Diabetes-related foot ulcers
- Surgical wounds
- Traumatic wounds

- Tunnelling wounds
- Partial thickness burns
- Wounds prone to bleeding following debridement



DURAFIBER° Ag range

# Some wounds require a dressing that is effective, easy to apply, and comfortable to the patient

### Designed with patients in mind

### Fast and highly absorptive properties<sup>12</sup>



Absorbs<sup>1,2</sup> and retains<sup>5</sup> fluid even under compression



Locks exudate and any pathogenic bacteria<sup>7</sup> into the dressing



Silver technology with antimicrobial activity<sup>8-10</sup>



Minimal Shrinkage<sup>1-2</sup> to conform intimately" to the wound bed 3,12

### Designed for optimal patient comfort<sup>a</sup>



Comfortable to the patient<sup>a</sup>



Fast gelling<sup>1,2</sup> provides a cool feeling when in contact with fluid



Easy to apply<sup>3</sup>



Intact one piece removal thanks to its high wet tensile strength



## know?

Our products can be used in conjunction with a secondary dressing such as ALLEVYN \$ 14-15






### Fast acting

DURAFIBER\* Ag has been demonstrated to start killing pathogens within 30 minutes<sup>13</sup> of contact and to possess an antimicrobial activity, effective for up to 7 days.

### Silver gelling mode of action


When DURAFIBER Ag comes into contact with exudate; the individual fibres hydrate and swell as they absorb wound fluid, forming a soft, cohesive gel sheet. As the fibres swell they lock in the absorbed exudate and the silver-containing gelled dressing matrix provides an antimicrobial action proven (in vitro) effective against a broad spectrum of bacteria including Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.8-10



Before application



Forming a gel upon contact with exudate<sup>3</sup>



Locks in exudate<sup>1,3,6</sup> and harmful bacteria<sup>7</sup> it may contain

## Ordering information

Item Code	Size	Units per carton
66800578	5cm x 5cm	Box/10
66800579	10cm x 10cm	Box/10
66800580	15cm x 15cm	Box/5
66800581	20cm x 30cm	Box/5
66800582	2cm x 45cm	Box/5
66800583	4cm x 10cm	Box/5
66800584	4cm x 20cm	Box/5
66800585	4cm x 30cm	Box/5

#### **DURAFIBER®** Ag

Antimicrobial action<sup>®</sup> with high absorption<sup>®</sup> and strength<sup>®</sup> for optimal patient comfort<sup>®</sup>.



#### Smith & Nephew Pty Ltd Australia

85 Waterloo Road North Ryde NSW 2113 PO Box 393 North Ryde NSW 1670 T+61 2 9857 3999 F +61 2 9857 3900

www.smith-nephew.com/australia

**Customer Service T** 13 13 60 F 1800 671 000

Smith & Nephew Ltd New Zealand

Unit A 36 Hillside Road Wairau Valley Auckland 0627 PO Box 316005 Wairau Valley Auckland 0760 T+64 9 820 2840

F +64 9 820 2841

www.smith-nephew.com/new-zealand

**Customer Service** T 0800 657 799 (Surgical) T 0800 807 663 (Wound)

\*Trademark of Smith & Nephew SN13943 (05/18)

Please consult product labels and package insert for indications, contraindications, hazards, warnings, cautions and instructions for use.

Supporting healthcare professionals

1. Giaffar L. Analytical and physical properties of DURAFIBER Ag recipe E. Data on file; 2016: report. DS/16/341/R. 2. Dowler A. DURAFIBER Ag (Recipe E) Testing. Data on file; 2015: report DS/15/269/R. 3. Forlee M, et al. A prospective, open, multicentre study to evaluate a new gelling fibre dressing containing silver in the management of venous leg ulcers. Int. Wound J 2014; 11:438-445. 4. Dowler A. Integrity testing of DURAFIBER Ag in horse serum and ionic solution. Data on file; 2012: report DS/12/093/DOF. 5. Giaffar L. DURAFIBER Ag recipe E absorption during compression. Data on file; 2016: report DS/16/443/R. 6. Lidster C. Sequestration testing of DURAFIBER Ag. Data on file; 2014: report DS/12/158/R2. 7. Lumb H. Visual demonstration of sequestration of Pseudomonas aeruginosa and Staphylococcus aureus in a DURAFIBER° Ag dressing using confocal microscopy. Data on file; 2014: report 1412017. 8. Lumb H. Antimicrobial activity of DURAFIBER° Ag against bacteria, yeast and fungi commonly found in wounds over a 7 day period. Data on file; 2015: report 1510009. 9. Lumb H. Antimicrobial activity of DURAFIBER® Ag against a broad spectrum of wound pathogens. Data on file; 2015: report 1510008. 10. Lumb H. Antimicrobial activity of DURAFIBER° Ag against bacteria, yeast and fungi commonly found in wounds over a 4 hour period. Data on file; 2015: report 15010010. 11. Lidster C. Intimate contact testing of DURAFIBER Ag. Data on file; 2014: report DS/12/143/R2. 12. Barrett S, et al. Case series evaluation: the use of DURAFIBER on exuding wounds. Wounds UK 2012; 8: 104-113. 13. Lumb H. Assessment of the contact kill activity of DURAFIBER Ag against common wound pathogens. Data on file; 2016: report 1609013. 14. Lidster C. Wound model testing of DURAFIBER Ag with various secondary dressings. Data on file; 2014: report DS/10/053/R2. 15. Blackburn I. DURAFIBER Ag can be used in conjunction with various secondary retentive dressing (ALLEVYN Life, ALLEVYN Non Adhesive, ALLEVYN Gentle Border, ALLEVYN Life and OPSITE). Data on file; 2014: Technical Justification Summary.